Biological and conformational evaluation of angiotensin II lactam bridge containing analogues

  title={Biological and conformational evaluation of angiotensin II lactam bridge containing analogues},
  author={Vani Xavier Oliveira and Marcos Antonio F{\'a}zio and Adriana Farias Silva and Patricia Targon Campana and Jo{\~a}o Bosco Pesquero and Edson Lucas Santos and Claudio M. Costa-Neto and Antonio Miranda},
  journal={Regulatory Peptides},

Figures and Tables from this paper

Angiotensin II analogues with N‐terminal lactam bridge cyclization: an overview on AT1 receptor activation and tachyphylaxis

To investigate the effect of N‐terminal cyclization on AT1 activation and tachyphylaxis, conformationally constrained analogues with an i‐(i + 1) lactam bridge were designed and some of them such as Cyclo (0‐1a) [Glu0, endo‐(Lys1a)]‐AngII and cyclic analogues showed higher potency.

Design, synthesis and biological evaluation of novel peptide MC2 analogues from Momordica charantia as potential anti-diabetic agents.

By screening in normal mice and mice with diabetes mellitus, peptides II-1, II-2 and III-3 showed a significant improvement in anti-hyperglycaemic and anti-oxidative activities compared with I-4, suggesting that II - (i + 2) lactam bridge could be candidates for future treatment of Diabetes mellitus.

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2

In this study, studies on the C-terminus of Ang II demonstrated varied specificity at different residue positions for ACE2 binding and four Ang II chimeric peptides were identified as selective ligands for the AT2 receptor.

Antiplasmodial activity study of angiotensin II via Ala scan analogs

The solid‐phase synthesis and characterization of eight peptides corresponding to the alanine scanning series of AII plus the amide‐capped derivative are presented, opening new perspectives toward the design of new sporozoiticidal compounds.

The Importance of Ring Size and Position for the Antiplasmodial Activity of Angiotensin II Restricted Analogs

This approach provides insight for understanding the effects of restricting the ring size and position on the bioactivity of angiotensin II and provides a new direction for the design of potential chemotherapeutic agents.

Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction

Angiotensin II (Ang II) is a natural mammalian hormone that has been described to exhibit antiplasmodial activity therefore constituting a promising alternative for the treatment of malaria. Despite

Evidences for the action mechanism of angiotensin II and its analogs on Plasmodium sporozoite membranes

Comparing the antimalarial activity of angiotensin II with that of (i) its diastereomer formed by only d‐amino acids; (ii) its isomer with reversed sequence; and (iii) its analogs restricted by lactam bridges, the so‐called VC5 peptides found AII to be much more flexible and able to experience both straight and coiled conformations.

Design, Synthesis, and Biological Evaluation of Novel Peptide Gly3‐MC62 Analogues as Potential Antidiabetic Agents

Two series of conformationally constrained analogues from Gly3‐MC62, designed by scanning the residues Lys1, Thr2, Met4, Lys5, Met7, and Ala8 with an i‐(i + 2) lactam bridge, showed significant improvement in antihyperglycemic and antioxidative activities and suggested that III‐4 could be candidate for the future treatment of diabetes mellitus.

New linear antiplasmodial peptides related to angiotensin II

This work presents the solid-phase syntheses and liquid chromatography and mass spectrometry characterization of ten linear peptides related to angiotensin II against mature P. gallinaceum sporozoites and erythrocyte invasion by P. falciparum and indicates that this class of peptides can be explored, as anti-malarial drugs, after in vivo model tests.

A study of the anti‐plasmodium activity of angiotensin II analogs

Kinetics studies indicate that the effects of these peptides on plasmodium viability overtime exhibit a sigmoidal profile and that the system stabilizes after a period of 1 h for all peptides examined.



Conformational restriction of angiotensin II: cyclic analogues having high potency.

Model building suggests that this ring structure of AII does not appear to accommodate a beta-turn or an alpha-helix which includes residues 3-5, which is consistent with a receptor-bound conformation having any of a variety of three-residue turns, including a gamma-turn.

Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II

The blood pressure response to the cyclic analogue was of less magnitude compared to that elicited by an isovolemic and equimolar solution of ANG II, and data confirm the importance of a properly oriented ring cluster, allowing the charge-relay conformation proposed for ANG II.

Novel synthesis of cyclic amide-linked analogues of angiotensins II and III.

Molecular modeling suggests that the ring structure of the potent analogue can be accommodated in the charge relay conformation proposed for ANGII.

Tachyphylactic properties of angiotensin II analogs with bulky and hydrophobic substituents at the N-terminus.

Tachyphylaxis, defined as the acute loss of response of some smooth muscles upon repeated stimulations with angiotensin II (Ang II), has been shown to be dependent mainly on the N-terminal region of

Influence of methylation of the histidine ring of [Sar1]angiotensin II on conformation and biological activity.

The high activity of the analogue methylated at His N3 suggests that an ionizable imidazole proton is not an absolute requirement for expression of biological activity by angiotensin ligands, and that the imidrazole group in the molecule may function in an ion dipole-based mechanism when an intramolecular proton transfer (charge relay) mechanism is not available.

Synthesis and biological activities of angiotensin II, Sarilesin, and Sarmesin analogues containing Aze or Pip at position 7.

Nuclear Overhauser effect (NOE) spectroscopy studies of [Sar1,Aze7]ANGII in DMSO-d6 have indicated a clustering of the three aromatic rings (Tyr, His, Phe) and proximity of Sar C alpha and Arg C delta protons to the Tyr/Phe ring protons.

Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.

Results suggest that the pituitary CRF receptor can discriminate between slightly different identifiable conformations, dramatically illustrating the role that secondary and tertiary structures play in modulating biological signaling through specific protein-ligand interactions.

Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.

The conformations of three angiotensin II (AII) peptide antagonists and the AII antipeptide, [Glu1,Gly2,Val5,Val8]-AII were assessed in a lipid medium to identify a common backbone turn.

Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.

Analysis of the conformational constraints imposed in these active analogs suggests that AII agonists bind to their receptor with different backbone conformations in the region of the central tyrosine residue.